Andrew co-founded Unilever Ventures in 2002. As a member of their Investment Committee he led their investments in Life Sciences and Personal Care before retiring from Unilever in December 2017. During his time at Unilever Ventures he acted as interim CEO of several of their portfolio companies. Andrew also sits on the Boards of P2i and IB Ventures Ltd. He was on the Board of BAC, CyDen and Pharmakodex before Unilever Ventures’ successful exits from these companies. Andrew joined Unilever as a marketing trainee in 1985 after studying Biochemistry at Cambridge University, qualified as a Chartered Management Accountant and has a general management, marketing and finance background.